Race to save more patients from permanent colostomy bags in rectal cancer trial
NCT ID NCT07277842
Summary
This study is testing whether adding an immunotherapy drug (serplulimab) to a strong chemotherapy regimen (FOLFOXIRI) and radiation works better than standard chemotherapy (CAPOX) and radiation for adults with locally advanced low rectal cancer. The goal is to shrink tumors before surgery to improve survival and increase the chance patients can avoid a permanent colostomy bag. Researchers will compare two groups of about 382 total participants to see which approach leads to better long-term outcomes and fewer cancer recurrences.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED LOW RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-Sen University Cancer Center
Guangzhou, None Selected, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.